MRK | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | |
SMR RATING 1..100 | 79 | |
PRICE GROWTH RATING 1..100 | 39 | |
P/E GROWTH RATING 1..100 | 2 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IYH | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 72% | 4 days ago 65% |
| Momentum ODDS (%) | 4 days ago 77% | 4 days ago 55% |
| MACD ODDS (%) | 4 days ago 78% | 6 days ago 56% |
| TrendWeek ODDS (%) | 4 days ago 80% | 4 days ago 57% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 42% |
| Advances ODDS (%) | 15 days ago 80% | 6 days ago 57% |
| Declines ODDS (%) | 12 days ago 79% | 12 days ago 51% |
| BollingerBands ODDS (%) | 5 days ago 82% | 4 days ago 63% |
| Aroon ODDS (%) | 4 days ago 81% | 7 days ago 62% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DDFS | 22.48 | 0.04 | +0.18% |
| Innovator Equity Dual Directional 15 Buffer ETF - September (DDFS) | |||
| PREF | 18.31 | -0.01 | -0.05% |
| Principal Spectrum Preferred Secs Active ETF (PREF) | |||
| BSCZ | 19.34 | -0.02 | -0.13% |
| Invesco BulletShares 2035 Corporate Bond ETF (BSCZ) | |||
| CRMU | 1.76 | -0.01 | -0.56% |
| Leverage Shares 2x Long CRML Daily ETF (CRMU) | |||
| GOLS | 25.50 | -0.15 | -0.57% |
| Gabelli Opportunities in Live and Sports ETF (GOLS) | |||
A.I.dvisor indicates that over the last year, IYH has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if IYH jumps, then LLY could also see price increases.
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.